Bringing Trial Activities to the Participant Lessons from the RADIAL Proof-of-Concept Trial The move toward more participant-centric clinical research has taken an important step forward. At the Clinical Pharmacology & Therapeutics journal, the first papers from the RADIAL trial, the flagship study of the Trials@Home project have now been published, offering valuable insights into how clinical research […]

The post Bringing Trial Activities to the Participant – Lessons from the RADIAL Proof-of-Concept Trial appeared first on Cambridge Cognition.

Speech Biomarkers for Alzheimer’s Disease Show Promise Across Multiple Languages The search for reliable, accessible biomarkers for early detection of cognitive decline has taken an important step forward. At AAIC 2025, our team presented data demonstrating that speech and language patterns can serve as valid digital biomarkers for Mild Cognitive Impairment (MCI) and Alzheimer’s disease […]

The post Speech Analysis as an Objective Biomarker in MDD Trials Speech Biomarkers for Alzheimer’s Disease Show Promise Across Multiple Languages appeared first on Cambridge Cognition.

CTAD | Posters & Presentations Hilton San Diego Bayfront, 1 Park Boulevard – San Diego, CA 92101 | 1-4th December We’re excited to announce we are attending the 18th Clinical Trials on Alzheimer’s Disease (CTAD) This year’s Clinical Trials on Alzheimer’s Disease (CTAD) conference brings together global leaders advancing research and innovation in Alzheimer’s and […]

The post CTAD | Posters & Presentations appeared first on Cambridge Cognition.

DIS | Posters & Presentations Pfizer Innovation Research (PfIRe Lab) 1 Portland St Cambridge, MA 02139 | 5th November 09:00am – 5:30pm PST We’re excited to announce that our team will be attending the 8th Annual Digital Implementation Summit   This year’s Digital Implementation Summit brings together global leaders driving the transformation of clinical development from […]

The post DIS | Posters & Presentations appeared first on Cambridge Cognition.

Closing the Gap Speech Analysis as an Objective Biomarker in MDD Trials The development of new therapies for Central Nervous System (CNS) disorders, particularly Major Depressive Disorder (MDD), is fundamentally challenged by the subjectivity and limitations of current assessment tools. Traditional measures, which often rely on patient self-reports or clinician ratings, frequently fail to capture […]

The post Closing the Gap – Speech Analysis as an Objective Biomarker in MDD Trials appeared first on Cambridge Cognition.

CTIS | Posters & Presentations Genentech, South San Francisco, CA, USA | 15th October 08:30am – 5:30pm PST We’re excited to announce that our team will be attending the 2nd Annual Clinical Trial Innovation Summit 2025   This years Clinical Trial Innovation Summit brings together global leaders driving the future of clinical research and we’re proud […]

The post CTIS | Posters & Presentations appeared first on Cambridge Cognition.

ISCTM and ECNP | Posters & Presentations Amsterdam, Netherlands | ISCTM: 9-11th October | ECNP: 11-14th October We’re excited to announce that our team will be attending the ISCTM 2025 Autumn Conference and ECNP 38th Congress 2025 This year’s program features world-class discussions on precision psychiatry, psychedelic therapies, and lessons from global clinical trials—and we’re proud to be […]

The post ISCTM and ECNP | Posters & Presentations appeared first on Cambridge Cognition.

How Picture Description Tasks Can Help Track Cognitive Health Remotely Speech as a digital biomarker in clinical research Changes in how we speak—how quickly we talk, how often we pause, and the words we choose—can be early signs of cognitive decline. People with mild cognitive impairment (MCI) or dementia due to Alzheimer’s disease (AD) often […]

The post How Picture Description Tasks Can Help Track Cognitive Health Remotely appeared first on Cambridge Cognition.

Cambridge Cognition Investment, Monument Therapeutics, Announces Partnership with Foundation for the National Institutes of Health for Clinical Trial of MT1988, a Novel Treatment for Schizophrenia 19 August 2025 Cambridge UK, August 19, 2025 – Cambridge Cognition (AIM: COG), the brain health software group specialising in digital health products that advance brain health research and treatment, is […]

The post Cambridge Cognition Investment, Monument Therapeutics, Announces Partnership with Foundation for the National Institutes of Health for Clinical Trial of MT1988, a Novel Treatment for Schizophrenia appeared first on Cambridge Cognition.

Cognition in The Blood (Biomarker) How do digital cognitive assessments relate to the Blood Plasma p-Tau217 in patients with Mild Cognitive Impairment (MCI)? Our latest research explores an exciting dataset with the AI–Mind Project, who have given us the opportunity to test the associations of our cognitive assessments alongside classic paper-and-pencil tests to levels of […]

The post Cognition in The Blood (Biomarker) appeared first on Cambridge Cognition.

Cambridge Cognition launches Speaker Identification Solution to Safeguard Clinical Trial Integrity 12 August 2025 Cambridge Cognition Holdings plc (AIM:COG), the brain health software group specialising in digital health products that advance brain health research and treatment, is pleased to announce the commercial launch of a proprietary speaker identification solution developed to tackle duplicate participant enrolment […]

The post Cambridge Cognition launches Speaker Identification Solution to Safeguard Clinical Trial Integrity   appeared first on Cambridge Cognition.

Trading update for period ended 30 June 2025 31st July 2025 Cambridge Cognition Holdings plc (AIM: COG), the brain health software group specialising in digital health products that advance brain health research and treatment, announces a trading update for the six months ended 30 June 2025. Highlights ·    New Sales Orders of £6.9m (H1 2024: £3.3m) ·    Order Book of £16.4m (30 […]

The post Trading update for period ended 30 June 2025 appeared first on Cambridge Cognition.

There is no excerpt because this is a protected post.

The post Protected: Integrating Blood-Based Biomarkers & Digital Cognitive Assessments to Accelerate Brain Health Research appeared first on Cambridge Cognition.

AAIC25 | Posters & Presentations Toronto, Canada | 27th – 31st July | Booth 1531 Unveiling Cutting-Edge Alzheimer’s & Dementia Research at AAIC 2025: A Sneak Peek at Our Latest Posters The Alzheimer’s Association International Conference (AAIC) is just around the corner, and we’re incredibly excited to share some of the latest research our team […]

The post AAIC25 | Posters & Presentations appeared first on Cambridge Cognition.

Cambridge Cognition Investment, Monument Therapeutics, Achieves Positive Phase I Results for Novel Schizophrenia Treatment 23rd June 2025 Cambridge Cognition (AIM: COG), the brain health software group specialising in digital health products that advance brain health research and treatment, is pleased to report that Monument Therapeutics, in which the Group has a 20% holding, has achieved […]

The post Cambridge Cognition Investment, Monument Therapeutics, Achieves Positive Phase I Results for Novel Schizophrenia Treatment appeared first on Cambridge Cognition.

SIRS 2025: Insights on Schizophrenia Research, From Rights Based Care to Digital Biomarkers Michael Spilka, Sr. Clinical Scientist This year’s Schizophrenia International Research Society (SIRS) 2025 Congress in Chicago brought together leading scientists and researchers, exploring the latest advancements and ongoing challenges in understanding and addressing schizophrenia. Michael Spilka, PhD. shares his key insights from […]

The post SIRS 2025: Insights on Schizophrenia Research, From Rights Based Care to Digital Biomarkers appeared first on Cambridge Cognition.

Spin-out Monument Therapeutics Announces Appointment of Robert Radie as Chair and Heather Preston to Advisory Board Thursday 17th April Manchester, UK, 17 April 2024 – Monument Therapeutics, a precision, neuroscience company focused on the development of innovative treatments forserious central nervous system disorders (CNS), today announced two key leadership appointments. Robert S. Radie (Bob) has […]

The post Monument Therapeutics Announces Appointment of Robert Radie as Chair and Heather Preston to Advisory Board appeared first on Cambridge Cognition.

Dementias Platform UK: TRANSLATION 2025 Martina De Lillo, Clinical Scientist We recently attended TRANSLATION 2025, organized by Dementia Platform UK, where experts shared groundbreaking developments in treatment approaches, diagnostic methods, and research methodologies. The presentations revealed a field undergoing rapid transformation, with significant implications for patients and healthcare professionals alike. The theme of the conference […]

The post Dementias Platform UK: TRANSLATIONS 2025 appeared first on Cambridge Cognition.

When to Use Standardised Assessments—And When You Might Need to Build Your Own Alex Kaula, Senior R&D Scientist Hello, I’m Alex Kaula, Senior R&D Scientist at Cambridge Cognition. If your research involves measuring cognitive function or clinical outcomes, you’ve likely faced this question: Should I use an established, validated assessment, or create a new one […]

The post When to Use Standardised Assessments—And When You Might Need to Build Your Own appeared first on Cambridge Cognition.

Cambridge Cognition Secures £1million Contract for Phase 3 Autoimmune Disease Trial 10 April 2025 Cambridge Cognition (AIM: COG), the brain health software group specialising in digital products to advance clinical research and patient treatment, has been selected by a major pharmaceutical company to provide digital cognitive assessments for a large Phase 3 autoimmune disease clinical […]

The post Cambridge Cognition Secures £1million Contract for Phase 3 Autoimmune Disease Trial appeared first on Cambridge Cognition.